Fertility and Sterility
Volume 92, Issue 4 , Pages 1360-1365, October 2009

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase

  • Michael von Wolff, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany
    • Corresponding Author InformationReprint requests: Michael von Wolff, Department of Gynecologic Endocrinology and Reproductive Medicine, University of Heidelberg, Voßstraße 9, 69115 Heidelberg, Germany (FAX: 49-6221-565356).
  • ,
  • Christian J. Thaler, M.D.

      Affiliations

    • Gynecologic Endocrinology and Reproductive Medicine, Women's Hospital, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Grosshadern, Germany
  • ,
  • Torsten Frambach, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of Wuerzburg, Wuerzburg, Germany
  • ,
  • Cosima Zeeb, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproduction, Women's Hospital of St. Gallen, St. Gallen, Switzerland
  • ,
  • Barbara Lawrenz, M.D.

      Affiliations

    • Women's Hospital, University of Tuebingen, Tuebingen, Germany
  • ,
  • Roxana M. Popovici, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany
  • ,
  • Thomas Strowitzki, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany

Received 2 April 2008; received in revised form 2 August 2008; accepted 7 August 2008. published online 20 October 2008.

Objective

To analyze if oocytes can be obtained in all patients before cancer treatment within 2 weeks by initiating ovarian stimulation during the follicular or luteal phase.

Design

Prospective controlled multicenter trial.

Setting

Four university-based centers.

Patient(s)

Forty cancer patients before chemotherapy.

Intervention(s)

Twenty-eight patients were stimulated with gonadotropins in the follicular phase (group I). In 12 patients (group II), ovarian stimulation was initiated in the luteal phase, and these received GnRH antagonists and recombinant FSH. In 14 patients, 143 oocytes were further processed for fertilization by intracytoplasmic sperm injection (ICSI).

Main Outcome Measure(s)

Number of oocytes aspirated after ovarian stimulation, cumulative FSH/hMG dosage, viability and maturity of oocytes, and fertilization rate by ICSI.

Result(s)

Patients in group I (age 27.6 ± 4.9 yrs) were stimulated on average for 10.6 days, and patients in group II (age 31.2 ± 5.7 yrs) for 11.4 days. Total amount of FSH was on average 2,255 IU (I) and 2,720 IU (II) per patient. Average and median numbers of aspirated oocytes were, respectively, 13.1 and 11.5 (I) versus 10.0 and 8.5 (II); 83.7% (I) and 80.4% (II) of the oocytes were mature and viable and could be treated by ICSI. Fertilization rate was 61.0% (I) versus 75.6% (II).

Conclusion(s)

This pilot study suggests that oocytes can be obtained before cancer treatment efficiently irrespective of the phase of the menstrual cycle.

Key Words: Cancer, ovarian stimulation, fertility preservation, luteal phase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 M.v.W. has nothing to disclose. C.T. has nothing to disclose. T.F. has nothing to disclose. C.Z. has nothing to disclose. B.L. has nothing to disclose. R.P. has nothing to disclose. T.S. has nothing to disclose.

PII: S0015-0282(08)03367-0

doi:10.1016/j.fertnstert.2008.08.011

Fertility and Sterility
Volume 92, Issue 4 , Pages 1360-1365, October 2009